Nothing Random About It: The State of Cancer Drug Development at FDA

FDA is getting tougher on cancer drug approvals. But stakeholders on all sides-industry, regulators, and patient groups-say that's probably a good thing. Under the leadership of Richard Pazdur, MD, the controversial director of FDA's newly formed Office of Oncology Drug Products, the agency is raising the bar for getting cancer drugs on the market.

By Ramsey Baghdadi

"Good drug, bad development." That is how Food & Drug Administration director of the Office of Oncology Drug Products Richard...

More from Leadership

More from In Vivo